Prescribing overview
Robaxin tablets are human products; injection has distinct vehicle-related precautions.
Key prescribing checks
- Human label warnings include central nervous system depression. Review concurrent sedatives and monitor for excessive sedation or impaired coordination.
- The injectable human label has additional formulation-related precautions, including renal pathology; do not transfer tablet assumptions to an injectable product.
- A human label establishes ingredient identity but does not provide an animal dose, approved veterinary indication or evidence of safety for every species.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Veterinary patients
Not established by reviewed human labelMuscle-relaxant use in animals is not approved by the reviewed tablet label.
Animal use requires a veterinarian's separate diagnosis and prescription.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Its effects may reflect CNS depression rather than direct skeletal-muscle relaxation.
Absorption, distribution, metabolism and elimination
Human volunteer kinetics must not be used to infer animal half-life.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Robaxin / Robaxin-750
Human oral tablets
Contraindications · when not to use
- Hypersensitivity to methocarbamol or tablet ingredients.
Precautions & monitoring
- Sedation and impaired coordination can occur; pregnancy safety is unestablished.
Robaxin
Human injection; distinct from listed tablets
Contraindications · when not to use
- Known or suspected renal pathology because of its polyethylene glycol vehicle.
- Hypersensitivity to methocarbamol or injection ingredients.
Precautions & monitoring
- Use cautiously with seizure disorders.
Human label; this does not establish veterinary approval or an animal treatment protocol.
Renal-pathology contraindication belongs to the injectable vehicle and must not be transferred to tablets.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Sedation, dizziness and impaired coordination are described in human labeling.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
A veterinary dose was not verified from an approved animal label; human dosing is not an animal regimen.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Robaxin / Robaxin-750
Human oral tablets
- Alcohol/other CNS depressants can add effects; pyridostigmine activity may be reduced.
Robaxin
Human injection; distinct from listed tablets
- CNS depressants can add effects.
Monitoring
Assess alertness and mobility and review other CNS depressants.
Client counseling
Follow the veterinary prescription; profound sedation or instability requires assessment.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Keep secured in the original labeled container; verify the current dispensed package.
Brands, formulations & ingredient identity
Active ingredients
Methocarbamol
Robaxin and Robaxin-750 contain methocarbamol in oral tablets. The numeric suffix is part of the product identity, not a separate active ingredient.
Robaxin injection is a different route and formulation; oral and injectable instructions cannot be exchanged.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Robaxin
- Formulation
- Oral tablet
- Label / product scope
- Human product
Human-labeled methocarbamol; availability varies by package.
Product label / source ↗Robaxin-750
- Formulation
- Oral tablet
- Label / product scope
- Human product
Strength-specific member of the Robaxin brand family.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.